Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer

Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer Acta Neurol Belg (2017) 117:753–755 DOI 10.1007/s13760-017-0751-5 LETTER TO THE EDITOR Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer 1 1 2 3 4 • • • • G. Turine A. Peeters C. Hermans S. Eeckhoudt T. Duprez Received: 18 November 2016 / Accepted: 17 January 2017 / Published online: 30 January 2017 Belgian Neurological Society 2017 Keywords Ischemic stroke  Intravenous thrombolysis  dabigatran 110 mg, which he immediately gave her. At Dabigatran  Idarucizumab 5.00 AM, he observed a right facial palsy. As symptoms did not resolve spontaneously, he called the emergency medical service. On admission, blood pressure was Introduction 170/100 mmHg, glycemia was 176 mg/dL, and cardiac rate was 98, irregular. Neurological examination showed Effective anticoagulation is a contraindication for intra- drowsiness, a right-sided paresis of face, arm, and leg, venous thrombolysis (IVT) with recombinant tissue plas- together with right-sided homonymous hemianopsia and minogen activator (rt-PA). We here report our first and severe aphasia. The total NIHSS score was 17. successful experience of systemic thrombolysis a few Brain computed tomography (CT) excluded an minutes after reversal of dabigatran by idarucizumab. intracranial hemorrhage and demonstrated an insular and left frontal acute http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Neurologica Belgica Springer Journals

Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer

Loading next page...
 
/lp/springer_journal/intravenous-thrombolysis-after-reversal-of-dabigatran-by-idarucizumab-XIv7EfGpR2
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Belgian Neurological Society
Subject
Biomedicine; Neurosciences; Neurology; Neuroradiology; Medicine/Public Health, general
ISSN
0300-9009
eISSN
2240-2993
D.O.I.
10.1007/s13760-017-0751-5
Publisher site
See Article on Publisher Site

Abstract

Acta Neurol Belg (2017) 117:753–755 DOI 10.1007/s13760-017-0751-5 LETTER TO THE EDITOR Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer 1 1 2 3 4 • • • • G. Turine A. Peeters C. Hermans S. Eeckhoudt T. Duprez Received: 18 November 2016 / Accepted: 17 January 2017 / Published online: 30 January 2017 Belgian Neurological Society 2017 Keywords Ischemic stroke  Intravenous thrombolysis  dabigatran 110 mg, which he immediately gave her. At Dabigatran  Idarucizumab 5.00 AM, he observed a right facial palsy. As symptoms did not resolve spontaneously, he called the emergency medical service. On admission, blood pressure was Introduction 170/100 mmHg, glycemia was 176 mg/dL, and cardiac rate was 98, irregular. Neurological examination showed Effective anticoagulation is a contraindication for intra- drowsiness, a right-sided paresis of face, arm, and leg, venous thrombolysis (IVT) with recombinant tissue plas- together with right-sided homonymous hemianopsia and minogen activator (rt-PA). We here report our first and severe aphasia. The total NIHSS score was 17. successful experience of systemic thrombolysis a few Brain computed tomography (CT) excluded an minutes after reversal of dabigatran by idarucizumab. intracranial hemorrhage and demonstrated an insular and left frontal acute

Journal

Acta Neurologica BelgicaSpringer Journals

Published: Jan 30, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off